Results 181 to 190 of about 13,220 (219)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study [PDF]
Lancet Infectious Diseases, The, 2016 Background Carbapenems are frequently the last line of defence in serious infections due to multidrug-resistant Gram-negative bacteria, but their use is threatened by the growing prevalence of carbapenemase-producing pathogens.
Yehuda Carmeli, Gregory G Stone
exaly +3 more sources
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia [PDF]
International Journal of Antimicrobial Agents, 2017 Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam plus ...
Min Ja Kim +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Ceftazidime/avibactam‐induced severe neutropenia: A case report
British Journal of Clinical Pharmacology, 2023AbstractCeftazidime/avibactam is an important option for the treatment of infections caused by multidrug‐resistant gram‐negative bacteria. Haematological abnormalities are rare adverse events. We describe a case of a 63‐year‐old male who developed severe neutropenia following exposure to ceftazidime/avibactam in the intensive care unit for the ...
Weifang Wu +3 more
openaire +2 more sources
Microbial Drug Resistance, 2022
We investigated the in vitro susceptibility of ceftazidime-avibactam (CZA) resistant Stenotrophomonas maltophilia to the associations aztreonam/amoxicillin-clavulanate (ATM-AMC) and ATM-CZA. Forty clinical isolates of S. maltophilia
Lise Crémet +6 more
openaire +3 more sources
We investigated the in vitro susceptibility of ceftazidime-avibactam (CZA) resistant Stenotrophomonas maltophilia to the associations aztreonam/amoxicillin-clavulanate (ATM-AMC) and ATM-CZA. Forty clinical isolates of S. maltophilia
Lise Crémet +6 more
openaire +3 more sources
International Journal of Antimicrobial Agents, 2014
For an antibacterial agent to be considered for clinical studies in nosocomial pneumonia (NP), it should be active in the presence of pulmonary surfactant. Furthermore, owing to the common practice of treating such infections with more than one antibacterial agent, it should be free of antagonistic interactions with agents of other classes.
John, Dallow +4 more
openaire +2 more sources
For an antibacterial agent to be considered for clinical studies in nosocomial pneumonia (NP), it should be active in the presence of pulmonary surfactant. Furthermore, owing to the common practice of treating such infections with more than one antibacterial agent, it should be free of antagonistic interactions with agents of other classes.
John, Dallow +4 more
openaire +2 more sources
Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections
The Consultant Pharmacist, 2015To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, dosing, and administration of ceftazidime/avibactam (CAZ/AVI).A search of PubMed using the terms "ceftazidime," "avibactam," "NXL104," and "AVE1330A" was performed. The manufacturer's website was also reviewed to further identify relevant
Elias B, Chahine +2 more
openaire +2 more sources
Ceftazidime/avibactam serum concentration in patients on ECMO
Journal of Antimicrobial ChemotherapyAbstract Objectives The use of extracorporeal membrane oxygenation (ECMO) may alter blood levels of several drugs, including antibiotics, leading to under dosing of these drugs and thus to potential treatment failure.
Anaïs Curtiaud +7 more
openaire +2 more sources